Your browser doesn't support javascript.
loading
Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels.
Allen, Mariet; Kachadoorian, Michaela; Quicksall, Zachary; Zou, Fanggeng; Chai, High Seng; Younkin, Curtis; Crook, Julia E; Pankratz, V Shane; Carrasquillo, Minerva M; Krishnan, Siddharth; Nguyen, Thuy; Ma, Li; Malphrus, Kimberly; Lincoln, Sarah; Bisceglio, Gina; Kolbert, Christopher P; Jen, Jin; Mukherjee, Shubhabrata; Kauwe, John K; Crane, Paul K; Haines, Jonathan L; Mayeux, Richard; Pericak-Vance, Margaret A; Farrer, Lindsay A; Schellenberg, Gerard D; Parisi, Joseph E; Petersen, Ronald C; Graff-Radford, Neill R; Dickson, Dennis W; Younkin, Steven G; Ertekin-Taner, Nilüfer.
Afiliación
  • Allen M; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
  • Kachadoorian M; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
  • Quicksall Z; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
  • Zou F; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
  • Chai HS; Department of Health Sciences Research, Mayo Clinic Minnesota, Rochester, MN 55905, USA.
  • Younkin C; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
  • Crook JE; Department of Health Sciences Research, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
  • Pankratz VS; Department of Health Sciences Research, Mayo Clinic Minnesota, Rochester, MN 55905, USA.
  • Carrasquillo MM; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
  • Krishnan S; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
  • Nguyen T; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
  • Ma L; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
  • Malphrus K; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
  • Lincoln S; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
  • Bisceglio G; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
  • Kolbert CP; Medical Genome Facility, Mayo Clinic Minnesota, Rochester, MN 55905, USA.
  • Jen J; Medical Genome Facility, Mayo Clinic Minnesota, Rochester, MN 55905, USA.
  • Mukherjee S; Department of Medicine, University of Washington, Seattle 98104, WA, USA.
  • Kauwe JK; Departments of Biology, Neuroscience, Brigham Young University, Provo, UT 84602, USA.
  • Crane PK; Department of Medicine, University of Washington, Seattle 98104, WA, USA.
  • Haines JL; Department of Molecular Physiology and Biophysics, and the Vanderbilt Center for Human Genetics Research, Vanderbilt University, Nashville, TN, USA ; Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH 44106, USA.
  • Mayeux R; Gertrude H. Sergievsky Center, Department of Neurology, and Taub Institute on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA.
  • Pericak-Vance MA; The John P. Hussman Institute for Human Genomics and Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, FL, USA.
  • Farrer LA; Departments of Biostatistics, Medicine (Genetics Program), Ophthalmology, Neurology, and Epidemiology, Boston University, Boston, MA, USA.
  • Schellenberg GD; Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
  • Parisi JE; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
  • Petersen RC; Department of Neurology, Mayo Clinic Minnesota, Rochester, MN 55905, USA.
  • Graff-Radford NR; Department of Neurology, Mayo Clinic Florida, 4500 San Pablo Road, Birdsall 3, Jacksonville, FL 32224, USA.
  • Dickson DW; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
  • Younkin SG; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
  • Ertekin-Taner N; Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA ; Department of Neurology, Mayo Clinic Florida, 4500 San Pablo Road, Birdsall 3, Jacksonville, FL 32224, USA.
Alzheimers Res Ther ; 6(4): 39, 2014.
Article en En | MEDLINE | ID: mdl-25324900
INTRODUCTION: MAPT encodes for tau, the predominant component of neurofibrillary tangles that are neuropathological hallmarks of Alzheimer's disease (AD). Genetic association of MAPT variants with late-onset AD (LOAD) risk has been inconsistent, although insufficient power and incomplete assessment of MAPT haplotypes may account for this. METHODS: We examined the association of MAPT haplotypes with LOAD risk in more than 20,000 subjects (n-cases = 9,814, n-controls = 11,550) from Mayo Clinic (n-cases = 2,052, n-controls = 3,406) and the Alzheimer's Disease Genetics Consortium (ADGC, n-cases = 7,762, n-controls = 8,144). We also assessed associations with brain MAPT gene expression levels measured in the cerebellum (n = 197) and temporal cortex (n = 202) of LOAD subjects. Six single nucleotide polymorphisms (SNPs) which tag MAPT haplotypes with frequencies greater than 1% were evaluated. RESULTS: H2-haplotype tagging rs8070723-G allele associated with reduced risk of LOAD (odds ratio, OR = 0.90, 95% confidence interval, CI = 0.85-0.95, p = 5.2E-05) with consistent results in the Mayo (OR = 0.81, p = 7.0E-04) and ADGC (OR = 0.89, p = 1.26E-04) cohorts. rs3785883-A allele was also nominally significantly associated with LOAD risk (OR = 1.06, 95% CI = 1.01-1.13, p = 0.034). Haplotype analysis revealed significant global association with LOAD risk in the combined cohort (p = 0.033), with significant association of the H2 haplotype with reduced risk of LOAD as expected (p = 1.53E-04) and suggestive association with additional haplotypes. MAPT SNPs and haplotypes also associated with brain MAPT levels in the cerebellum and temporal cortex of AD subjects with the strongest associations observed for the H2 haplotype and reduced brain MAPT levels (ß = -0.16 to -0.20, p = 1.0E-03 to 3.0E-03). CONCLUSIONS: These results confirm the previously reported MAPT H2 associations with LOAD risk in two large series, that this haplotype has the strongest effect on brain MAPT expression amongst those tested and identify additional haplotypes with suggestive associations, which require replication in independent series. These biologically congruent results provide compelling evidence to screen the MAPT region for regulatory variants which confer LOAD risk by influencing its brain gene expression.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Risk_factors_studies Idioma: En Revista: Alzheimers Res Ther Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Risk_factors_studies Idioma: En Revista: Alzheimers Res Ther Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido